TP53 and acute lymphoblastic leukemia: Different therapeutic strategies to target mutant p53 have been developed for the high risk TP53-mutant ALL, such as the use of the small molecule APR-246 which exhibits antileukemia activity in TP53mut BCP-ALL, targeting non-functional mutant p53 and restoring its tumor suppressive function [37].